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ABSTRACT
To obtain improved efficacy against pancreatic cancer, we investigated the 
efficacy and safety of a locally-applied 5-fluorouracil (5-FU)-loaded polymeric patch on 
pancreatic tumors in an orthotopic nude-mouse model. The 5-FU-releasing polymeric 
patch was produced by 3D printing. After application of the patch, it released the 
drug slowly for 4 weeks, and suppressed BxPC-3 pancreas cancer growth. Luciferase 
imaging of BxPC3-Luc cells implanted in the pancreas was performed longitudinally. 
The drug patch delivered a 30.2 times higher level of 5-FU than an intra-peritoneal 
(i.p.) bolus injection on day-1. High 5-FU levels were accumulated within one week 
by the patch. Four groups were compared for efficacy of 5-FU. Drug-free patch as 
a negative control (Group I); 30% 5-FU-loaded patch (4.8 mg) (Group II); 5-FU 
i.p. once (4.8 mg) (Group III); 5-FU i.p. once a week (1.2 mg), three times (Group 
IV). The tumor growth rate was significantly faster in Group I than Group II, III, IV 
(p=0.047 at day-8, p=0.022 at day-12, p=0.002 at day-18 and p=0.034 at day-21). 
All mice in Group III died of drug toxicity within two weeks after injection. Group II 
showed more effective suppression of tumor growth than Group IV (p=0.018 at day-
12 and p=0.017 at day-21). Histological analysis showed extensive apoptosis in the 
TUNEL assay and by Ki -67 staining. Western blotting confirmed strong expression 
of cleaved caspase-3 in Group II. No significant changes were found hematologically 
and histologically in the liver, kidney and spleen in Groups I, II, IV but were found 
in Group III.
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INTRODUCTION
More than 70% of operated pancreatic-cancer 
patients develop local or metastatic recurrence after 
attempted curative resection. Adjuvant chemotherapy has 
been shown to be somewhat effective in recent clinical 
trials, increasing the low median-survival rate two-fold 
[1-5]. Improved therapy for this recalcitrant disease is 
urgently needed. 
Since the amount of residual cancer cells is not 
large after pancreatic tumor resection, they can potentially 
be effectively eradicated with a small drug dose if it is 
properly delivered [6]. To improve adjuvant therapy of 
pancreatic cancer, we have designed a chemotherapeutic 
drug-loaded polymeric patch which can continuously 
administer small doses. 
In a previous report, we described a three-
dimensional printed (3DP) polymer patch loaded with 
a chemotherapy agent with controlled release and a 
manipulatable geometry which prevented tumor growth 
in a subcutaneous mouse model [6]. However, orthotopic 
models of pancreatic cancer are more patient-like since 
they are growing in a pancreatic micro-environment rather 
than a subcutaneous one [7-12]. 
In the present study, we investigated the efficacy 
and safety of the locally-applied chemotherapeutic-drug-
loaded polymeric patch in an orthotopic murine pancreatic 
cancer model. 
RESULTS AND DISCUSSION
Physical properties of the polymer patch
A schematic representation of a polymer patch and 
its implementation are shown in Figure 1A. The patch is 
described detailed in our previous publication [9]. The 
Figure 1: A. Schematic representation of the drug-loaded patch. B. Patch implantation process.
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shape and size of the patch are adjustable. The patch has 
an average weight of 8 mg, a size of 10 × 5 mm. The patch 
has a loop at each corner such that it can cover a tumor 
which has a three-dimensional round shape. The patch 
can be fixed at the desired site with suture. The surface of 
the patch with or without 5-FU was imaged with scanning 
electron microscopy (SEM) (Figure 2). 
 In vivo degradation was analyzed by implanting the 
patch onto the orthotopic pancreatic tumor and analyzed 
by SEM from the resected tumor as shown in Figure 2B. 
When the patch surface was examined by SEM three 
weeks after implantation on the orthotopic pancreatic 
tumor, we confirmed that the drug had been released 
through the orifices in the patch (Figure 2).
Figure 2: Physical properties of 5-FU-loaded patch. A. Optical microscopy of the 5-FU-loaded patch. Scale bar: 5 mm. B. 
Scanning electron microscopy (Left: Unloaded patch; Middle: 5-FU-loaded patch; Right: 5-FU-loaded patch after implantation in vivo for 
three weeks. C. Cumulative release profile of 5-FU loaded patch. D. Cytotoxicity of 5-FU-loaded patch in vitro. E. Patch-delivered 5-FU 
concentration in mouse pancreas tissue and blood serum.
Oncotarget40143www.impactjournals.com/oncotarget
In vitro efficacy of the patch on BxPC-3 cells
The amount of 5-FU released from the patch in 
vitro was measured using UV detection to verify the drug 
release function of the patch (Figure 2C). The patches 
weighed approximately 8 mg and were loaded with 30% 
w/w of 5-FU which is equivalent to 2.4 mg of drug per 
patch. The in-vitro release pattern of 5-FU showed an 
early burst release of approximately 26% of the drug 
within the first day. The drug was slowly released after 
that. The amount of eluted drug from day 7 to 28 was 
11-30 µg/ml (Figure 2C). BXPC-3 cell proliferation was 
inhibited more than 60% compared to untreated cells after 
four weeks (Figure 2D).
In vivo delivery of 5-FU to the pancreas by the 
patch
5-FU was injected (4.8 mg) i.p. once a week 
and compared with 5-FU delivery in animals with the 
patch. The pancreas was removed on days 1 and 8 after 
drug treatment. The amount of 5-FU in the pancreas 
was measured by liquid chromatography tandem-mass 
spectrometry (LC-MS/MS). In animals with the 5-FU-
loaded patch, the 5-FU level in the pancreas was 2.56 ± 
0.29 pg/mg on day 1; and 34.42 ± 8.12mg on day 8. In 
animals with i.p. delivery of 5-FU, the amount of 5-FU in 
the pancreas was 0.08 ± 0.02 pg/mg on day 1; and 0.01 ± 
0.00 pg/mg on day 8. The patch delivered a much larger 
Figure 3: A. In vivo luciferase images of growing orthotopic pancreatic tumors (IVIS Spectrum) (see Figure D). B. Quantitative imaging 
data of pancreatic-cancer growth are presented as mean ± SD. C. Correlation between tumor weight photon flux and D. tumor volume 
photon flux. Please see Materials and Methods for details. Data (n = 20) are presented as linear regression and Pearson correlation by 
GraphPad Prism.  P/S= photon/second.
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amount of drug to the pancreas and pancreatic tumor 
site than i.p. delivery (Figure 2E) (p = 0.018 at day 1, p 
= 0.024 at day 8). The 5-FU level in the blood had no 
significant difference at day 1, between animals with patch 
implantation and animals with bolus injection. However, 
a small amount of 5-FU (0.01± 0.00) was detected in the 
blood of a patch-implanted mouse at day 8. 
Efficacy of the patch on tumor growth
In untreated mice and mice implanted with a drug-
free patch, the orthotopic pancreatic cancer grew rapidly 
as shown by non-invasive imaging (Figure 3). The Pearson 
-correlation coefficient between tumor weight and image-
calculated volume was 0.914, and correlation between 
Figure 4: Antitumor efficacy of 5-FU-release patch. A. Tumor growth curves of treated and untreated mice (n = 6). *The mouse 
number changed in the 5-FU i.p. injection group with high dose (4.8mg) due to mouse death (n = 6 at day -4, -2, -1, 1, 6, 8; n = 2 at day 
12; and n = 1 at day 18, 21). B. Representative images of the treated and untreated tumors. C. Tumor weight and D. tumor volume at day 
21 after drug treatment. 
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Figure 5: Histological analysis. A. Images of hematoxylin and eosin (H&E)-stained pancreatic-cancer tissue sections from treated and 
untreated mice along with TUNEL and KI-67 staining for each condition. B. Cleaved caspase-3 from treated and untreated mice. H&E scale 
bar, 2 mm; fluorescence-image scale bar, 200 µm. Yellow-dotted line shows contact side of 5-FU-loaded patch.
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actual tumor volume and image-calculated volume was 
0.857. These results show that tumor-volume calculations 
obtained from the tumor image can reflect the actual tumor 
volume and weight.
In mice treated with i.p. 5-FU, non-invasive 
imaging showed continuous tumor-growth suppression 
but it was not significantly different from the untreated 
control (p = 0.132 at day 8, 0.057 at day 18 and 0.216 
at day 21). When 4.8 mg 5-FU was injected i.p. once, 
the growth of the pancreatic cancer was suppressed at 
the beginning. However, most of the mice died after two 
weeks, and the pancreatic cancer of one surviving mouse 
showed increased tumor growth after two weeks. The 
strongest tumor-suppression efficacy was with the patch 
implantation compared to animals implanted with an 
unloaded patch (Figure 4) (p = 0.031 at day 8, 0.002 at 
day 18 and 0.015 at day 21). 
At the end of the treatment period on day 21, tumors 
were resected from mice in each group and tumor volume 
and weight were directly measured. Both tumor weight 
and volume were significantly inhibited by the drug-
loaded patch (p = 0.029 for volume and p = 0.035 for 
weight). 5-FU delivered i.p. showed an inhibitory trend 
for tumor volume and weight but there is no significant 
difference (Figure 4D, 4E) for tumor volume (p = 0.434) 
or for tumor weight (p = 0.891).
Immunohistochemical staining of the treated 
pancreatic tumor
Most of the cells were stained with KI-67 and a few 
of them stained with TUNEL assay in the tumors covered 
with the sham patch (Figure 5A). In contrast, most cells 
around the adhesive face of the patch were stained with 
TUNEL in mice treated with the 5-FU-loaded patch and 
they did not stain with KI-67. However, some parts of the 
pancreatic cancer showed growth on the part of the tumor 
where the patch could not reach. Western blotting showed 
strong expression of cleaved caspase-3 indicating more 
apoptosis in the patch group than the control group (p = 
0.018) (Figure 5). The bolus-injection group also showed 
a similar pattern as the mice with the drug-loaded patch. 
However, in the bolus-treated mice, cells inside the tumor 
were stained with KI-67 (Figure 5B). 
Survival and hematological and histological 
toxicity
The experiment period was 28 days after cancer cell 
inoculation, which is not sufficient for metastasis to occur 
or to cause mouse death as a result of tumor growth. All 
Table 1: Hematologic parameters from mice with various treatments for one week
Hematology Unit
Control 5-FU patch 5-FU IP inj.(4.8mg, once)
5-FU IP inj.
(1.2mg, once/week)
Ave±SD Ave±SD Ave±SD Ave±SD
WBC 10e3/uL 7.12±2.01 5.18±0.58b 1.95±0.75b 4.68±0.31b
RBC 10e6/uL 10.00±0.28 8.86±0.14 4.49±0.64b 8.09±0.66
HGB g/dL 14.90±0.36 13.87±0.23 6.53±0.90b 12.57±1.08
HCT % 48.83±1.25 47.30±1.08 22.73±3.09b 43.57±2.65
PLT 10e3/uL 1259±58 1179.±454 1019±187 950±780
Neut 10e3/uL 0.53±0.22 0.62±0.16 0.04±0.01b 0.29±0.08b
Lymph 10e3/uL 6.27±1.75 4.28±0.33 1.88±0.73b 4.19±0.41
Mono 10e3/uL 0.07±0.02 0.07±0.03 0.00±0.00 0.04±0.01
Luc 10e3/uL 0.08±0.05 0.02±0.01 0.01±0.01b 0.04±0.03
%Retic % 3.56±0.09 9.49±1.40a 0.34±0.19b 18.38±14.37a
#Retic 10e9/L 356.23±14.87 839±112a 14.50±6.00b 1446±1061a
Data presented as mean±SD, n = 4. a and b represent significant increase and decrease at p < 0.05 compared to control values, 
respectively. 
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Figure 6: A. Survival rate of treated and untreated mice. B. H&E-stained liver (left panel), kidney (middle panel), and spleen (right panel) 
sections. Black arrow: pigment. Scale bar: 200 µm.
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mice treated with the sham patch, 5-FU-loaded patch and 
5-FU bolus injection with low dose survived until the end 
of the experimental period. However, for the mice treated 
with high-dose bolus 5-FU all died, except one, during 
the experimental period due to drug overdose (Figure 6A). 
All groups treated with 5-FU (patch and i.p.) showed 
a slight decrease in hematological values. However, in the 
high-dose (i.p.) group, most hematological factors such 
as WBC, RBC, HGB, HCT, etc., decreased more than 
50%, especially reticulocytes, which showed a decrease 
of more than 90% (Table 1). Histologically normal organs 
showed no difference between mice treated with the drug-
loaded patch and untreated animals. However, the spleen 
from a mouse injected with high dose 5-FU treated mouse 
showed loss of lymphoid tissue, fibrosis, and accumulation 
of iron pigment (Figure 6).
There was 33.5 times more 5-FU delivered to 
the pancreas with the patch than with a bolus i.p. 5-FU 
injection. With the patch, high levels of 5-FU remained 
in the pancreas even after one week, and was 21.9 times 
higher than bolus injection.
The orthotopic pancreatic cancer model is more 
appropriate for the patch than subcutaneous models, as 
the orthotopic mouse patch can be readily translated to 
the clinic. 
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [14-19]. 
CONCLUSION
The results of the present study show that a polymer 
patch constructed with 3D printing can release 5-FU for 
more than four weeks after attachment to the pancreas. 
Since the patch is directly attached to the organ, the 5-FU 
concentration in the blood is negligible but very high in 
the pancreatic tumor. The growth of pancreatic cancer 
was arrested by the patch with minimal toxicity. 3DP 
techniques have been previously demonstrated to produce 
implants that have precisely defined, micro- and macro 
architectures which can be applied effectively for complex 
release of multiple types of drugs [20-25]. In the clinic, 
the patch can be used after pancreatic cancer resection to 
prevent recurrence.
MATERIALS AND METHODS
5-FU-loaded polymer patch
A detailed description of patch production 
procedures can be found in our previous publication 
[6]. A polymer solution was prepared by melting 
polycaprolactone (PCL) (Polysciences, Inc. PA, USA) 
and poly(lactide-co-glycolide) (PLGA) (lactide: glycolide 
= 85:15, Sigma-Aldrich, MO, USA) at a ratio of 1:1 at 
140°C. 5-FU powder was mixed with the polymer solution 
at a 3:7 w/w ratio and loaded into the reservoir of a 3D 
printer. The mixture solution was extruded from the 
reservoir at 600 kPa in the printing head of an in-house-
manufactured extrusion-based 3D printer with a multi-
head deposition system (MHDS) [10].
Release profile of the 5-FU-loaded patch
The concentration of 5-FU released from the patch 
in PBS was determined by measuring the absorbance at λ 
= 265 nm using a UV-Vis spectrophotometer (Spectramax 
190, molecular device, CA USA).
Efficacy of 5-FU-releasing solution in vitro
BxPC3-Luc cells (3x103) were seeded into 96-
well plates for 24 hours prior to treatment (n = 4). 5-FU-
releasing medium or fresh complete culture medium 
was added to the wells. After 48 hours treatment with 
drug-releasing solution, cell viability was assessed 
using the Cell Counting Kit-8 (CCK-8) assay (Dojindo 
Laboratories, Kumamoto, Japan). The absorbance was 
measured using a microplate reader at 450 nm (Sunrise, 
TECAN, Switzerland). Cytotoxicity relative to control 
was determined.
Quantitation of 5-FU-released in the pancreas 
after patch implantation
5-FU-loaded (30%) patches in the pancreas of 
BALC/c nude mice were attached to the pancreatic tumors 
7-days after inoculation of BxPC3-Luc cells. 5-FU (1.2 
mg), dissolved in PBS, was injected on the same day, 
and 1.2 mg of the drug was once again injected a week 
after the first injection for comparison with the patch. 
The pancreas and serum were collected on the first day of 
patch implantation or drug treatment and on day 8 of the 
study as well. 
Analysis of 5-FU was performed with a liquid 
chromatography-tandem mass spectrometry system 
(LC-MS/MS). Glacial acetic acid (5 μl), ethyl acetate 
(500 μl), and internal standard solution (0.001 mg/ml 
5-bromouracil) (50 μl) were added to serum (50 μl) or 
tissue (50 mg). For tissue, the sample was homogenized 
using a TissueLyzer (Qiagen, Germany) and the 
supernatant was collected after centrifugation. For serum, 
the solution was mixed well for 5 min and centrifuged 
at 10,000 rpm for 5 min (Centrifuge 5415R, Eppendorf, 
Germany). The supernatant was transferred to a new 
tube. The supernatant was dried under vacuum, then 
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stored at -20°C until analysis. The dried material was 
reconstituted with acetonitrile (20 μl)/water/formic acid 
(97/3/0.1, v/v/v) before LC-MS/MS analysis. A LC-MS/
MS system equipped with a 1290 HPLC (Agilent), Qtrap 
5500 (ABSciex) and hydrophilic interaction column 
(Shodex Asahipak NH2P-50 2D column (5 μm, 150 × 
2 mm), Phenomenex, USA) was used. The separation 
gradient for 5-FU analysis used a mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic 
acid in acetonitrile) and proceeded at 300 µl/min at 
23°C. The separation gradient was as follows: hold at 
3-40% A for 3 min; 40 to 50% A for 1.6 min; 50 to 80% 
A for 1.4 min; hold at 80% A for 8 min; 80 to 0% A for 
1 min; 0 to 3% A for 2 min and then hold at 3% A for 
3 min. The multiple-reaction-monitoring (MRM) mode 
was used in negative-ion mode, and the extracted-ion 
chromatogram, corresponding to the specific transition 
(128.8/42.1 for 5-FU; 188.7/42.1 for 5-bromouracil), was 
used for quantification. The calibration range for 5-FU was 
0.0001−10 ng/ml (r2 ≥ 0.99). The background level of the 
untreated mice was used as a normalization control. 
Cell line
The BxPC3-Luc human pancreatic adenocarcinoma 
cell line, transduced with luciferase, was cultured in 
RPMI-1640 (RPMI; GIBCO) containing 10 % heat-
inactivation fetal bovine serum (FBS; GIBCO, MD, 
USA) and 1 % Antibiotic-Antimycotic (AA; GIBCO, 
MD, USA) in a humidified incubator at 37OC with 5% CO2 
atmosphere. BxPC3-Luc cells were selected in multiple 
steps and a clone was selected for high luciferase intensity. 
Mice
To prepare the xenograft mouse tumor model, 
BALB/c nude mice (Orient Bio Inc., Sungnam, Korea) 
were used (male, 6 weeks). All mouse experiments 
within the guidelines of the protocol were reviewed by 
the Institutional Animal Care and Use Committee of 
Asan Institute for Life Science [11]. BxPC-3-Luc cells 
were harvested (1×106) and resuspended in serum-free 
RPMI-1640 (10 µl) medium mixed with Matrigel (2:3 
ratio). After inhalational anesthesia with isoflurane, the 
entire pancreatic body and spleen were exposed to the 
outside of the peritoneal cavity using a blunt forceps, 10 
µl cells (1×106) in a Matrigel suspension were injected 
slowly using a 29 gauge syringe into the tail of the 
pancreas. The needle was removed from the pancreas 
and after a wait of 1-2 minutes, mice were inspected for 
hemorrhage and leakage. The pancreas and spleen were 
carefully repositioned back to the peritoneal cavity and 
the abdominal wall was closed with a 6.0 vicryl suture and 
abdominal skin closed using 5.0 black silk sutures [25]. 
Implantation of 5-FU-loaded patch
Two patches were fixed on the front and the back 
of the pancreas so that the drug could be delivered 
three-dimensionally (Figure 1B). Mice were randomly 
divided into 4 groups at day 7 after orthotopic cancer-cell 
inoculation; Group I: implanted with a drug-free patch 
(sham patch); Group II: implanted with a 30% 5-FU-drug-
loaded patch (4.8 mg); Group III: 5-FU i.p. injection once 
(4.8 mg); and Group IV: 5-FU i.p. injection once a week 
(1.2 mg), three times. All experimental groups started 
with n = 6 to 8 mice at the time of treatment initiation. 
Patches were surgically fixed on the pancreatic tumor. 
For i.p. injection, the 5-FU was dissolved in PBS and 
slowly injected on day 7. In group III, 4.8 mg of 5-FU was 
injected into the abdominal cavity once. In group IV, 1.2 
mg of 5-FU dissolved in PBS was injected once a week 
(day 0, 7, 14). 
Optical imaging of the orthotopic pancreatic 
tumor
Mice were intraperitoneally injected with D-luciferin 
(0.3 mg; Perkin Elmer Inc.). Whole-body luminescence 
imaging with an IVIS Spectrum (Caliper Inc., Alameda, 
CA) was performed every 3 minutes until radiance values 
reached the maximum. The region of the interested (ROI) 
level was measured with the radiance (photons/s/cm2/sr) 
using an analysis program, Living Image 4.4 (Caliper Life 
Sciences, PerkinElmer Inc.). 
Tumor measurement
The volume of the tumor was measured with 
calipers after removal at the end of the experiment. Tumor 
volume [mm3] = π/6 × (L) × (W) × (D). Tumors were also 
weighed. Tumor weight or volume were correlated to 
image size. 
Immunohistochemical staining
After sacrificing the mice at day 21, the tumors 
were removed and fixed in 4% neutral-buffered para-
formaldehyde and embedded in paraffin. Paraffin 
blocks were cut into 4 µm sections and were reviewed 
histologically after hematoxylin and eosin staining. 
Paraffin sections were deparaffinized and then rehydrated. 
After microwave antigen retrieval, non-specific binding 
sites were blocked with PBS containing 10% normal 
goat serum. The sections were further incubated with 
the primary antibodies against Ki-67 (Dako, Glostrup, 
Denmark) followed by an Alexa 488-conjugated 
secondary antibody (Thermo Fisher Scientific, 
Danvers, Massachusetts, USA). TUNEL staining was 
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performed using in situ cell-death detection kit (Roche 
Diagnostics GmbH, Mannheim, Germany) following the 
manufacturer’s protocol. The samples were mounted using 
Prolong Gold antifade mountant with DAPI (Thermo 
Fisher Scientific). Images were obtained using an EVOS-
fluorescence microscope (Thermo Fisher Scientific).
Western blotting
Protein samples were extracted from frozen 
tumors removed from sacrificed mice at day 21. For 
whole-lysate extraction, RIPA Lysis and Extraction 
Buffer (Biosensing, Seongnam, Republic of Korea) 
supplemented with a protease-inhibitor cocktail 
(Complete Mini, ethylenediaminetetraacetic acid-free; 
[Roche Diagnostics]) was used. The protein concentration 
of each sample was determined using a BCA protein 
assay kit (Thermo Fisher Scientific). Protein samples 
were resolved on a 10% polyacrylamide gel and were 
transferred onto nitrocellulose membranes (Trans-Blot® 
Turbo™ nitrocellulose; Bio-Rad, Hercules, CA). The 
membranes were blocked using 5% nonfat dry milk 
(AppliChem, Cheshire, CT, USA) in Tris-buffered saline 
Tween-20 (TBST; pH 7.6; 20 mM Tris-HCl, 150 mM 
NaCl and 0.1 % Tween 20) at room temperature (24oC) 
for 30 min and were incubated overnight at 4oC with 
cleaved caspase-3 rabbit monoclonal antibody (1:1000 
dilution, Cell Signaling Technology, Danvers, MA, USA). 
The membranes were then rinsed three times with TBST 
(pH 7.6) for 10 min at room temperature and incubated 
with horseradish peroxidase (HRP)-conjugated HRP-
conjugated goat anti-rabbit IgG (1:10000 dilution) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) at room 
temperature for 1 hr with gentle agitation. Membranes 
were washed five times with TBST (pH 7.6) for 30 min 
at room temperature. Protein signals were detected 
using an enhanced chemiluminescence (ECL) solution 
(SuperSignal™ West Femto; Thermo Fisher Scientific). 
Images were captured using an ImageQuant LAS 4000 
system (GE Healthcare Biosciences, Piscataway, NJ, 
USA). The blots were stripped using Restore™ PLUS 
(Thermo Fisher Scientific) stripping buffer and were 
reprobed for β-actin (internal control) using the same 
methods. Mouse monoclonal anti-human actin antibody 
(1:20000 dilution, Calbiochem, Darmstadt, Germany) 
was used as the primary antibody, and HRP-conjugated 
goat anti-mouse antibody (1:1000 dilution, Santa Cruz 
Biotechnology) was used as the secondary antibody. 
In vivo toxicity
BALB/c mice (7 weeks) were given an 
intraperitoneal injection of 4.8 mg 5-FU once or 1.2 
mg 5-FU once per week. Also, mice were treated by 
transplantation of two 5-FU-loaded patches (4.8 mg) or 
transplantation of sham patches. Mice were sacrificed 
on day 7 and samples of blood were taken from the 
abdominal vein. This experiment was performed in 
triplicate. All external features and orifices were visually 
examined and lesions which showed any abnormal 
morphology were recorded. Blood samples were collected 
for hematology determinations in tubes with EDTA-2 K 
as an anticoagulant. Hematology determinations included 
white-blood-cell (WBCs) count, red-blood-cell (RBC) 
count, hemoglobin concentration, hematocrit content, 
platelet count, differential leucocyte count (neutrophils, 
lymphocytes, monocytes), reticulocyte count, using an 
Advia 120 Hematology analyzer (Bayer Healthcare, 
Myerstown, PA, USA). The liver, spleen, and kidney, were 
analyzed for toxicity histologically. All organs/tissues 
were fixed in 10% neutral-buffered formalin and were 
processed and trimmed, embedded in paraffin, sectioned 
at a thickness of 4-6 µm, and stained with hematoxylin and 
eosin for microscopic examination. 
Statistical analysis
Statistical significance was determined using 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, 
USA) for tumor analysis. Data were analyzed by Pearson 
correlation for comparison of image size and tumor weight 
or volume. Survival among the groups was analyzed using 
the Log-Rank test for trend and pair-wise comparisons. 
The statistical significance of the differences between 
groups was analyzed with the Student’s t-test and a two-
way analysis of variance. P < 0.05 indicates a statistically-
significant difference. The data are presented as the 
mean ± standard deviation, with the number of samples 
indicated in the figure legends.
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